Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$154.79 - $180.76 $1.55 Million - $1.81 Million
10,000 Added 50.0%
30,000 $5.15 Million
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $1.6 Million - $1.82 Million
-10,000 Reduced 33.33%
20,000 $3.64 Million
Q4 2023

Feb 13, 2024

BUY
$137.6 - $154.97 $1.38 Million - $1.55 Million
10,000 Added 50.0%
30,000 $4.65 Million
Q1 2023

May 12, 2023

BUY
$144.61 - $166.54 $723,050 - $832,700
5,000 Added 33.33%
20,000 $3.19 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $2.07 Million - $2.49 Million
15,000 New
15,000 $2.43 Million
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $5.09 Million - $6.47 Million
-37,000 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$131.98 - $163.75 $395,939 - $491,250
-3,000 Reduced 7.5%
37,000 $6 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $1.06 Million - $1.21 Million
10,000 Added 33.33%
40,000 $4.32 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $3.07 Million - $3.38 Million
30,000 New
30,000 $3.25 Million
Q4 2020

Feb 16, 2021

SELL
$80.49 - $108.67 $3.22 Million - $4.35 Million
-40,000 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$85.91 - $100.83 $429,550 - $504,150
5,000 Added 14.29%
40,000 $3.5 Million
Q2 2020

Aug 14, 2020

BUY
$73.37 - $98.18 $2.57 Million - $3.44 Million
35,000 New
35,000 $3.44 Million
Q2 2018

Aug 14, 2018

SELL
$89.78 - $106.23 $538,680 - $637,380
-6,000 Closed
0 $0
Q1 2018

May 11, 2018

SELL
$92.01 - $123.21 $3.06 Million - $4.1 Million
-33,243 Reduced 84.71%
6,000 $568,000
Q4 2017

Feb 13, 2018

BUY
$89.56 - $98.21 $3.07 Million - $3.36 Million
34,243 Added 684.86%
39,243 $3.8 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $349,250 - $446,100
5,000
5,000 $444,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Advent Capital Management Portfolio

Follow Advent Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advent Capital Management , based on Form 13F filings with the SEC.

News

Stay updated on Advent Capital Management with notifications on news.